Pfizer Inc. (PFE)

36.57
0.26 0.71
NYSE : Health Technology
Prev Close 36.83
Open 36.79
Day Low/High 36.37 / 36.80
52 Wk Low/High 33.97 / 46.47
Volume 5.90M
Avg Volume 25.20M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 206.20B
EPS 1.90
P/E Ratio 16.59
Div & Yield 1.44 (3.81%)

Latest News

Pfizer Announces Positive Preliminary Results From A Proof-of-Concept Phase 2 Study (B7471003) Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Otitis Media In Healthy Infants

Pfizer Announces Positive Preliminary Results From A Proof-of-Concept Phase 2 Study (B7471003) Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Otitis Media In Healthy Infants

Pfizer Inc. (NYSE: PFE) announced today positive preliminary results following administration of three doses in a four-dose series for a Proof-of-Concept Phase 2 study (B7471003) to assess safety and immunogenicity of its 20-valent pneumococcal conjugate...

Have the FAANG Stocks Fallen From Favor?

Have the FAANG Stocks Fallen From Favor?

Mark Hulbert takes a look at the stocks most favored by the top-performing newsletters.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Chief Financial Officer and Executive Vice President, Global Supply and Business Operations, at the Morgan Stanley 17 th Annual Global...

Dow Ends Higher as Wall Street Gets Boost From Gains in Energy Sector

Dow Ends Higher as Wall Street Gets Boost From Gains in Energy Sector

Stocks finish higher as energy stocks rise on the back of higher oil prices.

Stocks End Down as Recession Worries Resurface, Trade Concerns Remain

Stocks End Down as Recession Worries Resurface, Trade Concerns Remain

Stocks finish down as recession worries again emerge and as investors monitor U.S. and China trade negotiations.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Union Pacific, Pfizer, Merck, AbbVie: 'Mad Money' Lightning Round

Jim Cramer takes a look at Union Pacific, Pfizer, Merck, AbbVie, Teva Pharmaceuticals, ABM Industries, Schlumberger and more.

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

XTANDI Supplemental New Drug Application (sNDA) Seeks to Add an Indication for Men with Prostate Cancer that Has Spread but Is Sensitive to Hormone Therapy

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review For The Treatment Of Men With Metastatic Hormone-Sensitive Prostate Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Pfizer Invests Half Billion Dollars To Advance State-of-the-Art Gene Therapy Facility In Sanford, North Carolina

Pfizer Invests Half Billion Dollars To Advance State-of-the-Art Gene Therapy Facility In Sanford, North Carolina

Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina.

Teva's Generic EpiPen Jr Is Now Available for $300

Teva's Generic EpiPen Jr Is Now Available for $300

There has been an EpiPen shortage in the U.S., Europe and Canada, thanks to manufacturing delays at Pfizer.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #20 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #299 spot.

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

GlycoMimetics Plummets After Phase 3 Trial of Sickle Cell Treatment Fails

The company announces that rivipansel, which was developed in partnership with Pfizer, didn't meet primary or secondary endpoints.

Pfizer Announces Phase 3 Top-Line Results For Rivipansel In Patients With Sickle Cell Disease Experiencing A Vaso-Occlusive Crisis

Pfizer Announces Phase 3 Top-Line Results For Rivipansel In Patients With Sickle Cell Disease Experiencing A Vaso-Occlusive Crisis

Pfizer Inc. (NYSE:PFE) announced today that the Phase 3 R ivipansel (GMI-1070): E valuating S afety, E fficacy and T ime to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints.

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline To Create A Premier Global Consumer Healthcare Company

Pfizer Announces Closing Of Joint Venture With GlaxoSmithKline To Create A Premier Global Consumer Healthcare Company

Pfizer Inc. (NYSE: PFE) today announced the closing of its joint venture with GlaxoSmithKline plc (NYSE: GSK) to combine the parties' respective consumer healthcare businesses to create the world's largest over-the-counter (OTC) business with robust...

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks Fall as Trump Casts Doubts on China Trade Deal, Fed Meeting Kicks Off

Stocks decline Tuesday as investors digest a plate full of earnings reports, the start of the two-day Fed meeting, and President Trump's remarks doubting the success of U.S. trade talks with China.

Pfizer Completes Acquisition Of Array Biopharma

Pfizer Completes Acquisition Of Array Biopharma

Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Array BioPharma Inc.

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Trading Apple and Netflix, Beyond Meat Earnings: Market Recon

Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V.

NEW YORK, July 29, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Mylan N.

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

While No Magic Pill, Mylan Deal Might Just Revive Drugmaker

The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Trading Pfizer Shares on Earnings, Tie-Up With Mylan

Pfizer reports earnings and announces a massive tie-up with Mylan, sending shares of the latter shooting higher.

A Look at Mylan's New Post-Merger Management

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.

It's Market Madness: Jim Cramer on Earnings Season, Pfizer and Mylan, Starbucks

It's Market Madness: Jim Cramer on Earnings Season, Pfizer and Mylan, Starbucks

Jim Cramer weighs in on Pfizer and Mylan, Starbucks and, of course, the causes for a week of market madness.

Pfizer to Combine Off-Patent Drug Division With Mylan

Pfizer to Combine Off-Patent Drug Division With Mylan

Mylan and Pfizer agreed to combine their off-patent drug businesses in an all-stock deal that will create a new company based in the United States.

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Grab Yourself a Cold Brew - Jim Cramer on Starbucks, Earnings and Mylan

Jim Cramer tackles Starbucks, the Federal Reserve, earnings and Mylan ahead of a week filled with potentially market-moving headlines.

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Mylan Will Bounce Today and Become Stronger on the Short-Term Charts

Pfizer is in talks to merge its off-patent drug operation with Mylan.

Mylan Jumps on Deal With Pfizer to Form New Company

Mylan Jumps on Deal With Pfizer to Form New Company

Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

Beyond Meat, Pfizer, Mylan, Amazon, Federal Reserve - 5 Things You Must Know

U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.

TheStreet Quant Rating: B (Buy)